(Q34467998)

2 August 2017

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid (English)

1 reference

2 August 2017

1 reference

ChEBI release 2020-05-28

Kantola T

1

1 reference

2 August 2017

Kivistö KT

series ordinal

2

1 reference

2 August 2017

Neuvonen PJ

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

Clinical Pharmacology & Therapeutics

2 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 August 2017

63

1 reference

2 August 2017

397-402

1 reference

2 August 2017

4

1 reference

Trough concentrations of cyclosporine in blood following administration with grapefruit juice

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Interaction of citrus juices with felodipine and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Interaction between grapefruit juice and midazolam in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Efficacy and long-term adverse effect pattern of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Drug-interaction-induced rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Drug interactions with grapefruit juice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Drug interactions with grapefruit: whose responsibility is it to warn the public?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

CYP3A gene expression in human gut epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990034-0

10.1016/S0009-9236(98)90034-0

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference